JPS6233208B2 - - Google Patents
Info
- Publication number
- JPS6233208B2 JPS6233208B2 JP51068675A JP6867576A JPS6233208B2 JP S6233208 B2 JPS6233208 B2 JP S6233208B2 JP 51068675 A JP51068675 A JP 51068675A JP 6867576 A JP6867576 A JP 6867576A JP S6233208 B2 JPS6233208 B2 JP S6233208B2
- Authority
- JP
- Japan
- Prior art keywords
- udp
- group
- present
- solution
- days
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 230000000259 anti-tumor effect Effects 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 5
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 claims description 2
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 claims description 2
- 229940045145 uridine Drugs 0.000 claims description 2
- 239000000243 solution Substances 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 239000002504 physiological saline solution Substances 0.000 description 10
- 206010039491 Sarcoma Diseases 0.000 description 8
- 238000002054 transplantation Methods 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 239000003708 ampul Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- TWFGREXFBVGQEU-UHFFFAOYSA-N 5-methyl-1,2-dihydrobenzo[j]aceanthrylene Chemical compound C1=CC2=CC=CC=C2C2=C1C(CC1)=C3C1=CC=C(C)C3=C2 TWFGREXFBVGQEU-UHFFFAOYSA-N 0.000 description 2
- TVEXGJYMHHTVKP-UHFFFAOYSA-N 6-oxabicyclo[3.2.1]oct-3-en-7-one Chemical compound C1C2C(=O)OC1C=CC2 TVEXGJYMHHTVKP-UHFFFAOYSA-N 0.000 description 2
- 208000006268 Sarcoma 180 Diseases 0.000 description 2
- 241000194107 Bacillus megaterium Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- PPQNQXQZIWHJRB-UHFFFAOYSA-N Methylcholanthrene Chemical compound C1=CC=C2C3=CC4=CC=C(C)C(CC5)=C4C5=C3C=CC2=C1 PPQNQXQZIWHJRB-UHFFFAOYSA-N 0.000 description 1
- 241000203578 Microbispora Species 0.000 description 1
- 241000187708 Micromonospora Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000187654 Nocardia Species 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Landscapes
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP6867576A JPS52151731A (en) | 1976-06-14 | 1976-06-14 | Tumor-inhibitory composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP6867576A JPS52151731A (en) | 1976-06-14 | 1976-06-14 | Tumor-inhibitory composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS52151731A JPS52151731A (en) | 1977-12-16 |
| JPS6233208B2 true JPS6233208B2 (de) | 1987-07-20 |
Family
ID=13380519
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP6867576A Granted JPS52151731A (en) | 1976-06-14 | 1976-06-14 | Tumor-inhibitory composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS52151731A (de) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK156252C (da) * | 1979-07-31 | 1989-12-18 | Fujisawa Pharmaceutical Co | Analogifremgangsmaade til fremstilling af di-, tri- eller tetrapeptidderivater eller salte deraf |
| JPS5645449A (en) * | 1979-07-31 | 1981-04-25 | Fujisawa Pharmaceut Co Ltd | Novel peptide, its pharmaceutically acceptable salt and preparation of the same |
| WO2000010587A1 (en) * | 1998-08-20 | 2000-03-02 | Incara Pharmaceuticals Corp. | Analogs of udp-murnac peptides, assays and kits |
-
1976
- 1976-06-14 JP JP6867576A patent/JPS52151731A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS52151731A (en) | 1977-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS6156134A (ja) | コラ−ゲン性医薬組成物 | |
| US5049396A (en) | Pharmaceutical compositions with anti-cancer activity and method for the treatment of cancer sensitive to treatment | |
| JPH0225415A (ja) | 癌転移抑制剤 | |
| US6720011B1 (en) | Injectable composition for cancer treatment | |
| JPS6233208B2 (de) | ||
| Chirigos et al. | Effectiveness of Cytoxan against intracerebrally and subcutaneously inoculated mouse lymphoid leukemia L1210 | |
| JPH07501534A (ja) | ガンの治療のためのクレアチンホスフェート又はホスホエノールピルビン酸の使用 | |
| US4343799A (en) | Use of derivatives of 6α-methylprednisolone for the prevention or reduction of adriamycin-induced cardiotoxicity | |
| JPS60501408A (ja) | 酸化剤ストレス誘導抗生物質に対する動物許容度を増加させる方法及び薬剤 | |
| Kassel et al. | Interferon-mediated oncolysis in spontaneous murine leukemia | |
| JPS6233209B2 (de) | ||
| Hagenbeek et al. | BCG treatment of residual disease in acute leukemia: studies in a rat model for human acute myelocytic leukemia (BNML) | |
| Carpenter et al. | Chemotherapy of murine leprosy | |
| Levi et al. | Serine derivative with antitumor activity | |
| JPH04502901A (ja) | シーピーエフペプチド組成物およびその用途 | |
| Yamasaki et al. | Reduction of hepatic metastases in rabbits by administration of an oily anticancer agent into the portal vein | |
| RU2523792C1 (ru) | Лекарственное средство для лечения туберкулеза | |
| WO2000043403A1 (fr) | Sels d'acide 2-methyl-3-butenyl-1-pyrophosphoriques et agents de traitement des lymphocytes | |
| JP3022915B2 (ja) | 癌転移抑制剤 | |
| Takeuchi et al. | Effect of Pluramycin A on Ehrlich Carcinoma of Mice Studies on Antitumor Substance Produced by Actinomycetes. XII | |
| UA70454A (en) | Antineoplastic platinum drug for treatment of non-antineoplastic platinum drug for treatment of non-small cell lung cancer and method for its usage small cell lung cancer and method for its usage | |
| Jackson | Treatment of superficial epitheliomatosis with an ointment containing demecolcin | |
| Nagler | Treatment of experimental gas gangrene due to Clostridium welchii with penicillin and antitoxin | |
| Grogan | Pseudomonas aeruginosa infection in mice after treatment with cyclophosphamide | |
| RU2308966C1 (ru) | Антиметастатическая композиция |